Moderna doses first patient with mRNA-1273 in coronavirus vaccine trial

This article was originally published here

Moderna has announced the dosing of the first participant in a phase1 study of mRNA-1273, the company’s mRNA vaccine candidate against the novel coronavirus (SARS-CoV-2). The early-stage study

The post Moderna doses first patient with mRNA-1273 in coronavirus vaccine trial appeared first on Pharmaceutical Business review.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply